News

What is the latest news in COVID-19 vaccines?

Published

on

As COVID-19 continues to spread, vaccines are still available to protect children from serious illness, hospitalization and death.

A vaccine against the SARS-CoV-2 virus is the best protection against severe illness, hospitalization, and death from COVID-19 infection. The COVID-19 vaccine is currently approved for use in patients aged 6 months and older. However, in the pediatric population, especially in children aged 6 months to her 4 years, vaccination was still very slow, of which only 7% received her 1 dose. Dose vaccination series 1.

As parents continue to debate whether to vaccinate their children, COVID-19 continues to rise in various communities across the country, and the Omicron BA.5 variant now accounts for nearly 90% of cases in the United States. 1 BA.5 is the most contagious of all the subspecies of COVID-19 and can evade immunity from previous infections and vaccination. The presence of high titers of antibodies to COVID-19 enhances protection against severe infections, hospitalizations and deaths from AD.5. This highlights the importance of getting vaccinated, including getting a booster if the vaccine is eligible.

Several new COVID-19 vaccines are currently being developed to combat the emergence of Omicron and its subspecies.

Pfizer and Moderna develop a specialized Omicron BA.4/BA.5 bivalent vaccine that includes a combination of his current COVID-19 vaccine and a candidate vaccine targeting the Omicron BA.4/BA.5 variant spike protein Did. Used as a booster dose. Preclinical data show that a booster dose of the matched bivalent Omicron BA.4/BA.5 vaccine is potent against the Omicron BA.1, BA.2, and BA.4/BA.5 variants, as well as the parental vaccine. shown to produce a neutralizing humoral response. A wild-type strain. These bivalent COVID-19 vaccines are expected to be available in fall 2022 as boosters for those 12 years and older.
A universal coronavirus vaccine is being developed that will protect against all current and future variants of COVID-19, as well as other coronaviruses such as SARS and Middle East Respiratory Syndrome coronavirus. Several different vaccine technology platforms have been explored to produce these vaccines, including harmless adenoviral vectors, mRNA, self-amplified RNA, and ferritin nanoparticles. One of these experimental vaccines, based on ferritin nanoparticle technology, has been tested in mouse and primate models and has shown good immune responses against various coronaviruses, including SARS-CoV-2. It has been shown to induce This experimental vaccine is in Phase 1 human clinical trials.
COVID-19 and its varieties are not going anywhere. Developing effective vaccines to prevent serious illness, hospitalization and death is the best preventative measure for people of all ages.

References

  1. Child and her COVID-19 vaccination trends. American Academy of Pediatrics. Updated 31 August 2022 Accessed 5 September 2022
  2. A. A. Cohen, N. Van Dremalen, A. J. Greaney. and others. Mosaic RBD nanoparticles protect against infection by various sarvecoviruses in animal models. Science. 2022;377(6606):eabq0839.Doi: 10.1126/science.abq0839
Click to comment

Trending

Exit mobile version